Previous 10 | Next 10 |
Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of genetic medicines for hearing loss and other therapeutic areas that are being advan...
2023-10-25 09:53:00 ET Over the past few years, we have witnessed several high-profile stock splits. Of course, these moves don't fundamentally change the value of a corporation. However, they can generate some buzz and renewed interest from investors, and allow people on a budget to acquir...
2023-10-25 09:25:00 ET Summary Bronte Capital is an Australian-licensed and USA SEC-registered Global Fund Manager and focuses on generating alpha from both its long and short portfolio in a unique, uncorrelated and sustainable manner. The Bronte Amalthea Fund achieved a 9.96% gai...
2023-10-25 08:30:32 ET Palm Beach, FL – October 25, 2023 – FinancialNewsMedia.com News Commentary – The R&D for cancer vaccines has been growing in the last few years and is projected to continue through the next decade. A cancer vaccine is used to eithe...
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-1...
2023-10-22 12:00:17 ET More on Gilead, Eli Lilly, etc. Gilead Sciences Stock Is Cheap, With Broad Pipeline Gilead Sciences: Does The Stocks Reward Outweigh The Risk Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Weig...
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of patients who experienced a pathologic complete response in the primary analysis TARRYTOW...
2023-10-20 17:46:51 ET More on Regeneron Pharmaceuticals, Sanofi Sanofi Q3 2023 Earnings Preview: Expect Positive Results, But No Share Price Spike Sanofi: 3 Reasons For A Buy Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare GoodRx to offer ...
TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Dupixen...
2023-10-19 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...